cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Rifki Febriansah
Contact Email
pharmrep1000@gmail.com
Phone
-
Journal Mail Official
pharmrep1000@gmail.com
Editorial Address
Jl. RS Fatmawati No 1. Pondok Labu Jakarta Selatan, 12450
Location
Unknown,
Unknown
INDONESIA
Pharmacy Reports
Published by Indonesian Young Scientist Group
ISSN : -     EISSN : 27989798     DOI : https://doi.org/10.51511/pr.2
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology
Pharmacy Reports is an open-access journal publishing peer-reviewed research in the pharmacy field, covering topics in pharmaceutics, biomedicine, pharmaceutical chemistry, bioinformatics, natural product, pharmacology and toxicology, and clinical pharmacy. Pharmacy Reports invites you to submit papers, covering topics in: pharmaceutics (pharmaceutical technology, drug delivery system), biomedicine (molecular biology, biochemistry, immunology, microbiology, biotechnology), pharmaceutical chemistry (analytical chemistry, medicinal chemistry: drug design, drug synthesis, pharmacochemistry, bioinformatic), natural product (fractionation, isolation, purification, and elucidation), pharmacology and toxicology (pharmacokinetics, toxicology), clinical pharmacy (therapeutic drug monitoring, adverse drug reaction, drug interaction), pharmaceutical industry, pharmacy education, community service related to pharmacy.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol. 4 No. 2 (2024): Pharmacy Reports" : 5 Documents clear
Evaluation of natural compounds as VEGFR-2 inhibitors for breast cancer therapy: insights from molecular docking and drug-likeness analysis Aprilia, Vika; Sarmoko; Fareza, Muhamad Salman; Baroroh, Hanif Nasiatul; Choironi, Nur Amalia
Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.82

Abstract

Breast cancer remains one of the most common cancers worldwide, with VEGFR-2 (KDR) playing a key role in tumor angiogenesis. Inhibiting VEGFR-2 is a promising therapeutic strategy. Natural compounds are increasingly studied for their potential to inhibit VEGFR-2. This study aims to assess the binding affinity of 11 natural compounds (andrographolide, alpha-mangostin, pinostrobin, pinocembrin, ethyl-p-methoxycinnamate (EPMS), xanthorrhizol, galangin, gamma-mangostin, curcumin, cinnamaldehyde, and alashanoid B) to the VEGFR-2 protein through molecular docking and Lipinski's rule analysis, identifying promising candidates for breast cancer treatment. Molecular docking simulations were performed for 11 compounds and sunitinib as a control, with binding energies and interactions analyzed. The compounds were also evaluated for drug-likeness using Lipinski’s rule of five. Curcumin showed the highest binding affinity to VEGFR-2 with a binding energy of -9.9 kcal/mol, surpassing sunitinib (-9.4 kcal/mol). Key interactions were observed with active site residues Cys919 and Asp1046. All tested compounds met the criteria for oral bioavailability per Lipinski’s rules. Curcumin demonstrates potential as a VEGFR-2 inhibitor due to its favorable binding affinity and drug-like properties. Enhancing curcumin’s bioavailability is recommended for effective therapeutic application.
The neuroprotective effects of Robusta coffee (Coffea canephora) on neurodegenerative diseases Warman, Ressalia Shoumadani; Iqbal, Muhammad; Triyandi, Ramadhan
Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.83

Abstract

Neurodegenerative diseases represent a growing global health challenge, particularly in aging populations. This review examines the neuroprotective potential of Robusta coffee (Coffea canephora) and its bioactive compounds in neurodegenerative conditions. Robusta coffee contains a rich profile of bioactive compounds, including caffeine, chlorogenic acids, and other polyphenols, which demonstrate significant antioxidant, anti-inflammatory, and neuroprotective properties. Evidence from preclinical and epidemiological studies suggests that these compounds can modulate multiple pathways involved in neurodegenerative processes, including oxidative stress, neuroinflammation, and protein aggregation. This review synthesizes current findings on the molecular mechanisms underlying the neuroprotective effects of Robusta coffee components in conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Recent advances in delivery systems, such as nanoparticle formulations, are also discussed as potential approaches to enhance the bioavailability and efficacy of coffee bioactives. By identifying the therapeutic potential of Robusta coffee components and highlighting gaps in current knowledge, this review provides a foundation for developing novel preventive and therapeutic interventions for neurodegenerative diseases based on these naturally occurring compounds.
Porang (Amorphophallus muelleri Blume) and its potential in diabetes management Jayaningsih, Ni Ketut Frida Murti; Nuratningsih, Ni Wayan; Wirawati, Ni Kadek Tania
Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.90

Abstract

Diabetes mellitus remains one of the most pressing global health challenges, driving the search for natural alternatives to conventional therapies. This review explores the potential of porang (Amorphophallus muelleri Blume) as a promising intervention for diabetes management. Porang is rich in glucomannan, a soluble dietary fiber with diverse therapeutic properties. Modern extraction methods can achieve glucomannan purity exceeding 90%, with ongoing advancements improving yield and quality. Mechanistically, porang exerts antidiabetic effects through multiple pathways, including enhanced insulin gene expression, improved insulin signaling, and reduced glucose absorption. Experimental studies in diabetic animal models demonstrate significant glucose-lowering effects, with blood glucose reductions of up to 50% alongside increased pancreatic β-cell counts. Beyond glycemic control, porang mitigates diabetic complications, reducing glomerulosclerosis and preserving reproductive function. It also offers broader metabolic benefits, such as improved lipid profiles, reduced inflammatory markers, and enhanced gut health via increased short-chain fatty acid production. While current evidence is promising, further clinical studies are needed to optimize dosing, formulations, and long-term efficacy in humans. Nevertheless, porang’s multifaceted therapeutic profile positions it as a viable complementary approach within comprehensive diabetes management strategies.
A bibliometric analysis of ginger's anticancer potential: bioactive compounds, cancer types, and mechanisms of action Maharani, Putu Audi Mas; Sarmoko
Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.91

Abstract

This study explores the anticancer properties of ginger (Zingiber officinale) through comprehensive bibliometric analysis of literature published from 2015 to 2024. Using PRISMA methodology, 49 relevant articles were identified from PubMed and analyzed through Biblioshiny and VOSviewer software. The International Journal of Molecular Sciences emerged as the leading publication source. Network visualization identified three major research clusters: antioxidant mechanisms, cancer biology, and phytochemical applications. Triple-negative breast cancer and colorectal cancer represent the most extensively studied malignancies. Mechanistically, ginger compounds (particularly gingerols and shogaols) demonstrate anticancer effects through multiple pathways including apoptosis induction, cell cycle arrest, anti-metastatic activity, oxidative stress modulation, and angiogenesis inhibition. While in vitro and preclinical evidence is robust, clinical translation remains limited. This analysis provides a comprehensive overview of ginger's anticancer research landscape, highlighting established mechanisms, identifying knowledge gaps, and suggesting future directions. The findings support ginger's potential as a complementary therapeutic agent and source of lead compounds for anticancer drug development, while emphasizing the need for advanced clinical investigations.
Molecular docking of hybrid coumarin thiazole derivative as anti-breast cancer on VEGFR-2 protein Liswatini, Putri; Rahma, Sophia; Mariska, Putri; Anggraeni, Fibria; Agustin, Desti; Sari, Desi Puspita; Afrian, Mahisa Shzara; Auli, Winni Nur; Saputro, Anjar Hermadi
Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.76

Abstract

VEGFR-2 is a tyrosine kinase receptor located on cell membranes, originally identified in endothelial cells but also expressed in tumor cells and various cancer types, including breast cancer. In breast cancer, VEGFR-2 expression is upregulated during early stages of primary tumors and invasive metastases, with elevated levels associated with lymph node metastasis and reduced survival outcomes. This computational study evaluated the potential of coumarin-thiazole derivative compounds against VEGFR-2 as anticancer agents using molecular docking analysis. Three coumarin-thiazole hybrid compounds (42a, 54a, and 54b) were assessed for their binding affinity to VEGFR-2, with sorafenib serving as the reference drug. The docking analysis utilized the three-dimensional structure of VEGFR-2 (PDB ID: 2OH4) downloaded from the RCSB Protein Data Bank. Ligand structures were prepared using molecular modeling software and converted to appropriate formats for analysis. Molecular docking was performed using AutoDockTools v.1.5.7, and protein-ligand interactions were visualized using BIOVIA Discovery Studio 2024 software.Method validation using the native GIG ligand yielded a binding energy of -10.88 kcal/mol. The binding energy values for the three test compounds were -9.81 kcal/mol for compound 42a, -12.71 kcal/mol for compound 54a, and -12.77 kcal/mol for compound 54b. Compound 54b demonstrated the strongest binding affinity to VEGFR-2, surpassing the native ligand GIG, the reference drug sorafenib, and the other test compounds. These results indicate that compound 54b represents the most promising candidate for anti-breast cancer therapy through VEGFR-2 targeting, warranting further experimental validation.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2024 2024


Reset
Filter By Issues
All Issue Vol. 5 No. 3 (2025): Pharmacy Reports Vol. 5 No. 2 (2025): Pharmacy Reports Vol. 5 No. 1 (2025): Pharmacy Reports Vol. 4 No. 3 (2024): Pharmacy Reports Vol. 4 No. 2 (2024): Pharmacy Reports Vol. 4 No. 1 (2024): Pharmacy Reports Vol. 3 No. 3 (2023): Pharmacy Reports Vol. 3 No. 2 (2023): Pharmacy Reports Vol. 3 No. 1 (2023): Pharmacy Reports Vol. 2 No. 3 (2022): Pharmacy Reports Vol. 2 No. 2 (2022): Pharmacy Reports Vol. 2 No. 1 (2022): Pharmacy Reports Vol. 1 No. 2 (2021): Pharmacy Reports Vol. 1 No. 1 (2021): Pharmacy Reports More Issue